PubMed Health⌕ Search

Biomedical subjects

Patrick Cougard

Publications and source records attributed to Patrick Cougard.

6 recordsLinked to original sources
PubMed2006

Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE.

BACKGROUND: The management of small, nonfunctioning pancreaticoduodenal endocrine tumors (NFPET) in multiple endocrine neoplasia type 1 (MEN1) patients is still controversial. We therefore investigated the effect of surgery on survival and tumor progression in MEN1 patients with NFPET < or = 2 cm by analyzing data from the Groupe des Tumeurs Endocrines (GTE) registry. MATERIALS AND METHODS: Among 579 MEN1 patients in the registry, 65 had NFPET < or = 2 cm. Fifteen (23%) underwent pancreatectomy, 9 at least segmental pancreatectomies and 6 biopsies or enucleations (the surgery group), and 50 (77%) were followed conservatively (the no surgery group). Age at MEN1 and NFPET diagnosis was similar in both groups, as was size of the primary tumor. Seven (10.8%) patients had metastases. Five metastases were synchronous, and 2 (one in each group) were metachronous. Tumor size was similar in patients with or without metastasis. RESULTS: There was no perioperative mortality. The average follow-up time after NFPET diagnosis was 6.7 years in the surgery group and 3.3 years in the no surgery group. Three (4.6%) patients died during follow-up, 2 due to NFPET and 1 due to thymus tumor. The 2 patients who died of NFPET had undergone pancreatic surgery at the time of NFPET diagnosis. The 2 groups did not differ significantly with respect to tumor progression [5/15 (33%) vs 6/38 (16%), P = 0.16]. Overall life expectancy of patients with NFPET < or = 2 cm was not different than that of the 229 MEN1 patients in the registry without any pancreaticoduodenal tumor (P = 0.33). CONCLUSIONS: This study suggests that surgery may not be beneficial for MEN1 patients with NFPET < or = 2 cm.

Adult↗
PubMed2006

Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas.

OBJECTIVE: To analyze the penetrance and clinical course of isolated nonfunctioning tumors of the pancreas (NFTP) in MEN 1 patients, and to propose a strategy for managing them. SUMMARY BACKGROUND DATA: Pancreaticoduodenal tumors develop in a majority of MEN 1 patients and are a major cause of death. The natural history of NFTP is poorly defined, and no clear-cut guidelines have been widely accepted regarding treatment. METHODS: Data on 108 patients with isolated NFTP among 579 MEN 1 patients from the French Endocrine Tumor Study Group (GTE) were analyzed. Survival rates were calculated using the Kaplan-Meier method. RESULTS: The penetrance of NFTP was 34% at age 50, making it the most frequent pancreaticoduodenal tumor in MEN 1 patients. Forty-three patients (40%) underwent surgery, 32 of them curatively. No patient died because of surgery. Average life expectancy for patients with NFTP was shorter than that for MEN 1 patients who did not have pancreaticoduodenal tumors. Thirteen patients died during follow-up, 10 due to NFTP. Tumor size was correlated with the risks of metastasis and death. These risks were low for patients with tumors<or=20 mm. CONCLUSIONS: NFTP are currently the most common tumors of the pancreaticoduodenal region in patients with MEN 1. Prevention of tumor spread by surgery should be balanced with potential operative mortality and morbidity. We do not recommend routine surgery for NFTP<or=20 mm.

Adolescent↗
PubMed2004

[Levator ani syndrome, functional intestinal disorders and articular abnormalities of the pelvis, the place of osteopathic treatment].

OBJECTIVES: Various treatments of the Levator ani syndrome (LVAS) have been proposed. None of them alleviate symptoms in more than 20% of the cases. A new approach combining massages of the coccygeus muscle with physical treatment of frequently associated pelvic joint disorders was assessed. The outcome of the Irritable Bowel Syndrome (IBS) that is frequently associated was also studied. METHODS: One hundred and one patients (76 females and 25 males, mean age: 54 years) with a diagnosis of LVAS were studied prospectively over one year. Massages were given with a patient lying on the left side. Physical treatment of the pelvic joint disorders was given at the end of each massage session. RESULTS: Forty-seven patients (46.5%) suffered both from LVAS and IBS. A mean of less than 2 sessions of treatment was necessary. Sixty-nine per cent of the patients were LVAS-free at 6 months (p<0.0001) and 10% were improved. At 12 months, 62% were still free of symptoms and 10% improved (p=0.37). A comparable trend according to the Rome II criteria was found in the IBS-patient group (53% IBS free initially, 78% at 6 months [p=0.00001], 72% at 12 months [p=1]). There was a significant correlation between the favorable outcome of IBS and the LVAS at 6 and 12 months. All IBS-free patients were LVAS-free at 6 months. CONCLUSION: The LVAS may be cured or alleviated in 72% of the cases at 12 months with one to 2 sessions. This new comprehensive treatment suggests the role of a muscular and osteoligamentary etiology in the LVAS. Since most of IBS benefitted from such treament, it is logical to suspect a mutual pathogeny and to screen for LVAS in all such patients.

Adult↗
PubMed2003

[Diaphragmatic hernia].

A diaphragmatic hernia is the protrusion of abdominal contents into the thoracic cavity, via a hole in the diaphragm, which either presence or size is abnormal. Congenital hernias are rare and often diagnosed at birth. Adults are diagnosed accidentally. Symptoms can be digestive or respiratory, and the risk of volvulus calls for surgery. Diaphragmatic ruptures are seen more often, and are a consequence of violent thoraco-abdominal trauma, or penetrating wound. They should be treated surgically in emergency, but the operation can be delayed if they are not diagnosed at once. Videosurgery has been used more and more often recently to treat diaphragmatic hernias.

Abdominal Injuries↗
PubMed2002

Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.

To date, data on pituitary adenomas in MEN type 1 (MEN1) still have to be evaluated. We analyzed the data of a large series of 324 MEN1 patients from a French and Belgian multicenter study. Data on pituitary disease were compared with those from 110 non-MEN1 patients with pituitary adenomas, matched for age, year of diagnosis, and follow-up period. Genetic analysis of the MEN1 gene was performed in 197 of the MEN1 patients. In our MEN1 series, pituitary disease occurred in 136 of 324 (42%), less frequently than hyperparathyroidism (95%, P < 0.001) and endocrine enteropancreatic tumors (54%, P < 0.01). Mean age of onset of pituitary tumors was 38.0+/-15.3 yr (range, 12-83 yr). Pituitary disease was associated with hyperparathyroidism in 90% of cases, with enteropancreatic tumors in 47%, with adrenal tumors in 16%, and with thoracic neuroendocrine tumors in 4%. Pituitary disease was the initial lesion of MEN1 in 17% of all MEN1 patients. MEN1 pituitary adenomas were significantly more frequent in women than in men (50% vs. 31%, P < 0.001). Among the 136 pituitary adenomas, there were 85 prolactinomas and 12 GH-secreting, 6 ACTH-secreting, 13 cosecreting, and 20 nonsecreting tumors. Eighty-five percent of MEN1-related pituitary lesions were macroadenomas (vs. 42% in non-MEN1 patients, P < 0.001), including 32% of invasive cases. Among secreting adenomas, hormonal hypersecretion was normalized, after treatment, in only 42% (vs. 90% in non-MEN1 patients, P < 0.001), with a median follow-up of 11.4 yr. No correlation was found between the type of MEN1 germ-line mutation and the presence or absence of pituitary adenoma. Our study, based on a large group of MEN1 patients, shows that pituitary adenomas occur in 42% of the cases and are characterized by a larger size and a more aggressive presentation than without MEN1.

Adenoma↗